Chairman's Message

With the launch of Ryaltris™ in the foreseeable future, we mark the first major milestone in our strategic roadmap that envisages specialty and innovative products contributing 30% of our revenues by 2025.

Glenn Saldanha,Chairman & Managing Director
Read more

Glenmark at a Glance

In the last 40 years, Glenmark has grown from an India-based organisation with a single dermatology product to a global pharmaceutical company. Today, it has more than 6,000 products worldwide that include offerings in Respiratory, Dermatology and Oncology therapeutic areas.

Adding Value through Differentiated and Innovative Offerings

Glenmark is well on its way to establishing itself globally as an innovation-led pharmaceutical company. We are just a few steps away from launching our first branded, specialty product in the global market in the respiratory segment. Our Novel Molecular Entities (NMEs), the pipeline built over a decade of investments in new drug research and development (R&D), are making progress in the clinic.

Bringing Quality Medicines
to Patients all over the World

Over the last decade, Glenmark has evolved into a global organisation. Whether it is the developed markets of the US and Europe or emerging economies in Asia, Africa and Latin America,

NME & Specialty Pipeline

Glenmark has a robust pipeline of nine compounds in various stages of clinical development, primarily focused in the areas of Respiratory, Dermatology, Oncology and Pain.

Creating an Enriched Experience for Glenmarkians

As an organisation, we believe that our success relies on the collective success of our people. The Glenmark philosophy inculcates the spirit of entrepreneurship amongst Glenmarkians by empowering them with the freedom to drive business outcomes independently.

Promoting Sustainable Growth through Corporate Responsibility

At Glenmark, we are committed to the philosophy of paving ‘a new way for a new world’, with an unwavering focus on helping address the unmet needs of the society.

Management Discussion & Analysis

The overall global growth is projected to reach 3.9% in 2018 and 2019, in line with the forecast of the April 2018 World Economic Outlook (WEO), but the expansion is becoming less even, and risks to the outlook are mounting.